South Easton, MA, May 1, 2008 /PRNewswire-FirstCall/ -- Pressure BioSciences, Inc. (Nasdaq: PBIO - News) (“PBI”) today announced that total revenue for the first quarter of 2008 was $132,376 compared to $131,621 for the comparable period in the prior year. Revenue from the sale of PCT products and services was $81,473 for the three months ended March 31, 2008 as compared to $37,943 for the prior year period. During the first quarter of 2008, we completed the installation of seven PCT Sample Preparation Systems (“PCT Systems”), as compared to one in the first quarter of 2007. Also contributing to the increase in revenue was an increase in the number of PULSE Tubes and ProteoSolve-lrs kits sold. The Company also recorded $50,903 of grant revenue during the first quarter of 2008 as compared to $93,678 in the same period in the prior year. This decrease in grant revenue was due to a shift in resources from grant related activities to other research and development projects.

Mr. Myles continued: “As noted previously, our stated commercialization strategy is centered upon increasing the installed base of PCT Sample Preparation Systems so that we can continue to realize increases in our recurring revenue streams from PULSE Tubes, ProteoSolve-lrs kits, and extended service contracts. During the first quarter of 2008, we saw an increase in sales of our PULSE Tubes and ProteoSolve products. We believe this is an indication that scientists who have adopted our technology are using PCT to address their sample preparation needs for a greater portion of their experiments.”

Mr. Schumacher continued: “The number of calls we have received related to our PCT product line has continued to increase, as has the number of requests for PCT System quotations for grant submissions. We have made measurable progress on our 2008 goals related to the development of a new PCT instrument, a new PCT consumable, and a new ProteoSolve kit. Our sales team is benefiting tremendously from the leadership of our newly hired (February 25, 2008) Vice President of Sales, Mr. Matthew Potter. We look to the remainder of 2008 with enthusiasm as we believe our achievements in the first quarter of 2008 position us well to accomplish our 2008 commercialization goals of converting research scientists who are excited about our technology into revenue-generating customers and active supporters of the PCT Sample Preparation System.”

Pressure BioSciences, Inc. (PBI) is a publicly-traded company focused on the development of a novel, enabling technology called pressure cycling technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 6 foreign patents covering multiple applications of PCT in the life sciences field, including in such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of chemical reactions, immunodiagnostics, and protein purification.

Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements include statements regarding the Company’s expectations for 2008, the anticipated benefits and results of the Company’s sales force efforts, and beliefs regarding the validation of the Company’s technology due to the Company’s sales of PCT Systems and consumables. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: possible difficulties or delays in the implementation of the Company's strategies that may adversely affect the Company's continued commercialization of its PCT Sample Preparation System; changes in customers needs and technological innovations; if the Company's expenses are higher than anticipated or if the Company's revenues do not increase, the Company may not have sufficient cash to support its planned activities and the Company may be unable to obtain financing on acceptable terms; the Company’s sales force may not be successful in selling the Company’s PCT product line because scientists may not perceive the advantages of PCT over other sample preparation methods; and the Company may be unable to develop new PCT-related products that are perceived by potential customers as having advantages over current technologies and techniques. Additional risks and uncertainties that could cause actual results to differ materially from those indicated by these forward-looking statements are discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

Consolidated Statements of Operations
	For the Three Months Ended
	March 31,

	2008			2007

REVENUE:
PCT Products, services, other	$	81,473		$	37,943
Grant revenue		50,903			93,678
Total revenue		132,376			131,621

COSTS AND EXPENSES:
Cost of PCT products and services		48,449			31,654
Research and development		490,931			461,532
Selling and marketing		463,161			256,530
General and administrative		501,248			481,082
Total operating costs and expenses		1,503,789			1,230,798
Operating loss from continuing operations		(1,371,413	)		(1,099,177	)

OTHER INCOME:
Realized gain on securities available for sale		-			727,473
Interest income		30,308			71,602
Total other income		30,308			799,075
Loss before income taxes		(1,341,105	)		(300,102	)
Income taxes from continuing operations		-			40,519
Loss from continuing operations		(1,341,105	)		(259,583	)

DISCONTINUED OPERATIONS:

Loss on discontinued operations		-			(378,503	)
Net loss	$	(1,341,105	)	$	(638,086	)

Loss per share from continuing operations - basic and diluted	$	(0.61	)	$	(0.13	)
Loss per share from discontinued operations - basic and diluted		-			(0.18	)
Net loss per share - basic and diluted	$	(0.61	)	$	(0.31	)

Weighted average number of shares used to calculate loss per share - basic and diluted		2,192,175			2,065,425

Consolidated Balance Sheets
	March 31,			December 31,
ASSETS	2008			2007

CURRENT ASSETS
Cash and cash equivalents	$	4,146,820		$	5,424,486
Accounts receivable		106,867			118,471
Inventories		595,060			172,548
Deposits		211,561			553,483
Prepaid income taxes		58,463			56,863
Income tax receivable		249,541			249,541
Prepaid expenses and other current assets		220,407			94,783
Total current assets		5,588,719			6,670,175

PROPERTY AND EQUIPMENT, NET		339,713			257,797

OTHER ASSETS
Intangible assets, net		316,132			328,290
TOTAL ASSETS	$	6,244,564		$	7,256,262

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES
Accounts payable	$	378,609		$	152,729
Accrued employee compensation		364,144			377,190
Accrued professional fees and other expenses		189,642			186,840
Income taxes payable		5,889			4,519
Deferred revenue		9,911			15,075
Total current liabilities		948,195			736,353

LONG TERM LIABILITIES
Deferred revenue		6,127			6,767
TOTAL LIABILITIES		954,322			743,120

COMMITMENTS AND CONTINGENCIES

STOCKHOLDERS' EQUITY
Preferred stock; 1,000,000 shares authorized; 0 outstanding		-			-
Common stock, $.01 par value; 20,000,000 shares authorized;
2,192,175 shares issued and outstanding		21,922			21,922
Additional paid-in capital		6,402,821			6,284,616
Retained (deficit) earnings		(1,134,501	)		206,604
Total stockholders' equity		5,290,242			6,513,142
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$	6,244,564		$	7,256,262

Richard T. Schumacher, President & CEO	Pressure BioSciences, Inc.
Edward H. Myles, Senior Vice President of Finance & CFO	(508) 230-1828 (T)